Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (NCT06421675) | Clinical Trial Compass
RecruitingPhase 2
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Canada40 participantsStarted 2025-03-28
Plain-language summary
A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Relapsed and/or refractory MM defined as:
✓. Documented evidence of progressive disease (PD) after achieving at least minimal response (MR) for ≥ 1 cycle during a previous MM treatment (i.e., relapsed MM).
✓. Disease progression during or within 60 days from the end of the most recent MM treatment (i.e., refractory MM).
✓. Measurable disease based on IMWG criteria, defined as at least one of the following, documented within 28 days before enrollment:
✓. Serum M-protein ≥ 0.5 g/dl.
✓. Urine M-protein excretion ≥ 200 mg/24 h.
✓. Serum-free light chains (FLC) assay: Involved FLC level ≥ 10 mg/dl (≥ 100 mg/l) AND an abnormal serum-free light chain ratio (\< 0.26 or \> 1.65) only for patients without measurable serum or urine M protein.
✓. Receipt of at least three prior classes of drugs either in separate regimens or as combinations.
Exclusion criteria
✕. Active plasma cell leukemia (either 20% of peripheral white blood cells or \> 2.0 × 109/L circulating plasma cells by standard differential).